April 19, 2017 NIAID Funding News
Read this full issue online at https://www.niaid.nih.gov/
In Part III of our series about popular relocated content, we cover the Apply for a Grant section—located within the “Grants & Contracts” tab of the top navigation bar.
Opportunities and Resources
NIH’s Centers for AIDS Research program supports research coordination, emerging research opportunities, and shared core facilities among institutions that receive significant HIV/AIDS funding from NIH.
A new request for proposals seeks services to develop multiple vaccines and biologic candidates that emerge from third-party sources.
NIAID anticipates awarding 10 multiple award indefinite quantity contracts and expects the performance period to begin summer of 2018.
For a limited time, administrative supplements are available to fund collaborative pilot projects seeking to reduce the incidence or severity of auto-inflammatory or autoimmune adverse events following cancer immunotherapy.
In The News
Investigators who want to accelerate dissemination and enhance the rigor of their work can now cite interim research products anywhere other research products are cited in a grant application or progress report.
The 21st Century Cures Act provides funding to further the field of regenerative medicine using adult stem cells, including autologous cells.
- Your Application Will Be Withdrawn if You Don’t Follow NIH’s Appendix Policy
- R03, R21 Opportunities on Primary Immunodeficiency Diseases Will Expire Early
- Several BD2K Roadmap Initiatives Cancelled, New Initiatives Planned
Having trouble distinguishing between direct and indirect costs for your federally funded research project? We’ve listed a few key points to help you better understand the difference.
New Funding Opportunities
- PAR-17-254, Lasker Clinical Research Scholars Program (Si2/R00)
- RFA-AI-17-010, Dysregulation of Immune Cell Regulatory Pathways by Mtb in the Context of HIV Infection (R61/R33)
See other announcements at Opportunities & Announcements.
Send suggestions or comments to email@example.com.